|
Part I Bayesian Methods In Biomedical Research |
|
|
|
1 An Application of Bayesian Approach for Testing Non-inferiority Case Studies in Vaccine Trials |
|
|
3 | (14) |
|
|
|
|
|
|
|
2 Bayesian Design of Noninferiority Clinical Trials with Co-primary Endpoints and Multiple Dose Comparison |
|
|
17 | (18) |
|
|
|
|
|
|
|
|
|
3 Bayesian Functional Mixed Models for Survival Responses with Application to Prostate Cancer |
|
|
35 | (26) |
|
Veerabhadran Baladandayuthapan |
|
|
|
|
|
|
|
|
4 Bayesian Predictive Approach to Early Termination for Enriched Enrollment Randomized Withdrawal Trials |
|
|
61 | (14) |
|
|
|
Part II Diagnostic Medicine and Classification |
|
|
|
5 Estimation of ROC Curve with Multiple Types of Missing Gold Standard |
|
|
75 | (14) |
|
|
|
|
|
6 Group Sequential Methods for Comparing Correlated Receiver Operating Characteristic Curves |
|
|
89 | (20) |
|
|
|
|
|
7 Nonparametric Covariate Adjustment for the Youden Index |
|
|
109 | (24) |
|
|
|
|
|
8 Comparative Effectiveness Research Using Meta-Analysis to Evaluate and Summarize Diagnostic Accuracy |
|
|
133 | (16) |
|
|
|
|
|
|
|
|
|
|
|
Part III Innovative Clinical Trial Designs and Analysis |
|
|
|
9 Some Characteristics of the Varying-Stage Adaptive Phase II/III Clinical Trial Design |
|
|
149 | (14) |
|
|
|
10 Collective Evidence in Drug Evaluation |
|
|
163 | (22) |
|
|
|
11 Applications of Probability of Study Success in Clinical Drug Development |
|
|
185 | (12) |
|
|
|
12 Treatment Effect Estimation in Adaptive Clinical Trials: A Review |
|
|
197 | (6) |
|
|
|
|
|
13 Inferiority Index, Margin Functions, and Hybrid Designs for Noninferiority Trials with Binary Outcomes |
|
|
203 | (32) |
|
|
|
14 Group-Sequential Designs When Considering Two Binary Outcomes as Co-Primary Endpoints |
|
|
235 | (28) |
|
|
|
|
|
|
|
|
|
|
|
15 Issues in the Use of Existing Data: As Controls in Pre-Market Comparative Clinical Studies |
|
|
263 | (10) |
|
|
|
16 A Two-Tier Procedure for Designing and Analyzing Medical Device Trials Conducted in US and OUS Regions for Regulatory Decision Making |
|
|
273 | (12) |
|
|
|
|
|
|
|
17 Multiplicity Adjustment in Seamless Phase II/III Adaptive Trials Using Biomarkers for Dose Selection |
|
|
285 | (18) |
|
|
|
|
|
|
|
|
|
Part IV Modelling and Data Analysis |
|
|
|
18 Empirical Likelihood for the AFT Model Using Kendall's Rank Estimating Equation |
|
|
303 | (10) |
|
|
|
|
|
19 Analysis of a Complex Longitudinal Health-Related Quality of Life Data by a Mixed Logistic Model |
|
|
313 | (16) |
|
|
|
20 Goodness-of-Fit Tests for Length-Biased Right-Censored Data with Application to Survival with Dementia |
|
|
329 | (18) |
|
|
|
|
|
|
|
21 Assessment of Fit in Longitudinal Data for Joint Models with Applications to Cancer Clinical Trials |
|
|
347 | (20) |
|
|
|
|
|
|
|
|
|
|
|
22 Assessing the Cumulative Exposure Response in Alzheimer's Disease Studies |
|
|
367 | (14) |
|
|
|
|
|
|
|
|
|
|
|
23 Evaluation of a Confidence Interval Approach for Relative Agreement in a Crossed Three-Way Random Effects Model |
|
|
381 | (14) |
|
|
|
|
|
Part V Personalized Medicine and Subgroup Analysis |
|
|
|
24 Assessment of Methods to Identify Patient Subgroups with Enhanced Treatment Response in Randomized Clinical Trials |
|
|
395 | (16) |
|
|
|
|
|
|
|
|
|
25 A Framework of Statistical Methods for Identification of Subgroups with Differential Treatment Effects in Randomized Trials |
|
|
411 | (16) |
|
|
|
|
|
|
|
26 Biomarker Evaluation and Subgroup Identification in a Pneumonia Development Program Using SIDES |
|
|
427 | (42) |
|
|
|
|
|
|
|
|
|
|
|
Part VI Statistical Genomics and High-Dimensional Data Analysis |
|
|
|
27 A Stochastic Segmentation Model for the Indentification of Histone Modification and DNase I Hypersensitive Sites in Chromatin |
|
|
469 | (26) |
|
|
|
|
|
|
|
|
|
|
|
28 Combining p Values for Gene Set Analysis |
|
|
495 | (24) |
|
|
|
|
|
29 A Simple Method for Testing Global and Individual Hypotheses Involving a Limited Number of Possibly Correlated Outcomes |
|
|
519 | |
|
|
